Micrograph of an epithelioid angiosarcoma. Credit: Nephron.

Tracon Pharmaceuticals has terminated the Phase III TAPPAS clinical trial conducted to assess TRC105 plus Votrient (pazopanib) in advanced or metastatic angiosarcoma patients.

The move comes after a review by the Independent Data Monitoring Committee (IDMC) found that the combination did not lead to clinically meaningful efficacy.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The IDMC analysed interim unblinded safety and efficacy findings from more than 120 participants.

TRC105 is an oncology formulation of carotuximab and an antibody to the endoglin protein, which is overexpressed on proliferating endothelial cells required for the formation of new blood vessels.

“We are disappointed that TRC105 in combination with Votrient did not demonstrate clinically meaningful efficacy.”

TAPPAS was intended to evaluate TRC105 in combination with Votrient, compared to Votrient alone, in a total of 340 subjects. Tracon started dosing patients in the trial in February 2017.

The trial’s primary endpoint was progression-free survival. Its secondary endpoints included objective response rate, safety, overall survival, and tolerability.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Based on the TAPPAS results, the company has decided to terminate further enrolment into its trials of TRC105 in oncology indications.

Tracon Pharmaceuticals president and CEO Charles Theuer said: “We are disappointed that TRC105 in combination with Votrient did not demonstrate clinically meaningful efficacy in patients with advanced or metastatic angiosarcoma.

“On a financial note, as a result of the expected savings to be generated from terminating TRACON sponsored trials of TRC105, we anticipate our current cash runway will now extend into the third quarter of 2020.”

Under a licence to Santen Pharmaceutical, Tracon is also developing an ophthalmic formulation of TRC105, called DE-122, for the treatment of wet age-related macular degeneration.

DE-122 is currently in Phase II AVANTE trial for wet AMD patients.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now